Deep brain stimulation for epilepsy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The efficacy and safety of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) for epilepsy (SANTE) trial was demonstrated by a randomized trial by Fisher et al. (2010). Based on this trial, the U.S. Food and Drug Administration recently granted approval for DBS therapy for epilepsy; the indication is as follows: “Bilateral stimulation of the anterior nucleus of the thalamus (ANT) for epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial onset seizures with or without secondary generalization that are refractory to three or more antiepileptic medications”. This paper reviews the experimental data and the clinical experience using DBS for the treatment of epilepsy.

Original languageEnglish (US)
JournalEpilepsy and Behavior
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Deep Brain Stimulation
Epilepsy
Anterior Thalamic Nuclei
Seizures
Partial Epilepsy
United States Food and Drug Administration
Anticonvulsants
Therapeutics
Safety

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Deep brain stimulation for epilepsy. / Salanova, Vicenta.

In: Epilepsy and Behavior, 01.01.2018.

Research output: Contribution to journalArticle

@article{c17665f4e68048efa00e22b140a87980,
title = "Deep brain stimulation for epilepsy",
abstract = "The efficacy and safety of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) for epilepsy (SANTE) trial was demonstrated by a randomized trial by Fisher et al. (2010). Based on this trial, the U.S. Food and Drug Administration recently granted approval for DBS therapy for epilepsy; the indication is as follows: “Bilateral stimulation of the anterior nucleus of the thalamus (ANT) for epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial onset seizures with or without secondary generalization that are refractory to three or more antiepileptic medications”. This paper reviews the experimental data and the clinical experience using DBS for the treatment of epilepsy.",
author = "Vicenta Salanova",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.yebeh.2018.06.041",
language = "English (US)",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Deep brain stimulation for epilepsy

AU - Salanova, Vicenta

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The efficacy and safety of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) for epilepsy (SANTE) trial was demonstrated by a randomized trial by Fisher et al. (2010). Based on this trial, the U.S. Food and Drug Administration recently granted approval for DBS therapy for epilepsy; the indication is as follows: “Bilateral stimulation of the anterior nucleus of the thalamus (ANT) for epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial onset seizures with or without secondary generalization that are refractory to three or more antiepileptic medications”. This paper reviews the experimental data and the clinical experience using DBS for the treatment of epilepsy.

AB - The efficacy and safety of deep brain stimulation (DBS) of the anterior nucleus of the thalamus (ANT) for epilepsy (SANTE) trial was demonstrated by a randomized trial by Fisher et al. (2010). Based on this trial, the U.S. Food and Drug Administration recently granted approval for DBS therapy for epilepsy; the indication is as follows: “Bilateral stimulation of the anterior nucleus of the thalamus (ANT) for epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial onset seizures with or without secondary generalization that are refractory to three or more antiepileptic medications”. This paper reviews the experimental data and the clinical experience using DBS for the treatment of epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=85049873711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049873711&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2018.06.041

DO - 10.1016/j.yebeh.2018.06.041

M3 - Article

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

ER -